Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

BackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Medicine
Subjects:
RET fusion
non-small-cell lung cancer
pralsetinib
survival outcomes
prognostic factors
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1467871/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2025.1467871/full

Similar Items